Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55–...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidiqi, M. Hasib, Aljama, Mohammed A., Bin Riaz, Irbaz, Dispenzieri, Angela, Muchtar, Eli, Buadi, Francis K., Warsame, Rahma, Lacy, Martha Q., Dingli, David, Leung, Nelson, Gonsalves, Wilson I., Kapoor, Prashant, Kourelis, Taxiarchis V., Hogan, William J., Rajkumar, S. Vincent, Kumar, Shaji K., Gertz, Morie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224498/
https://www.ncbi.nlm.nih.gov/pubmed/30409963
http://dx.doi.org/10.1038/s41408-018-0147-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224498/
https://www.ncbi.nlm.nih.gov/pubmed/30409963
http://dx.doi.org/10.1038/s41408-018-0147-7

Ejemplares similares